Marilu O Byrne, MD
Ophthalmology · Mandeville, LANPI 1083772453
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), gifts and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 26.1% of the total. Reporting peaked in 2019 at $6,141 and has fallen 73.3% since, to $1,643 in 2025. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $47.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$4K
- Johnson & Johnson Surgical Vision, Inc.$3K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$832
- Oyster Point Pharma, Inc.$709
- Bausch & Lomb Americas Inc.$642
- plus $4K from 19 others
What the payments were for
- Consulting fees$2,00013%
- Travel & lodging$7865%
- Food & beverage$8,29155%
- Gifts$3,96326%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 1 | $3,924 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $3,391 |
| AbbVie(2 entities) | 76 | $1,850 |
| Sun Pharmaceutical Industries Inc. | 42 | $832 |
| Oyster Point Pharma, Inc. | 23 | $709 |
| Bausch & Lomb Americas Inc. | 22 | $642 |
| Alcon | 22 | $602 |
| Novartis | 34 | $548 |
| Glaukos Corporation | 6 | $519 |
| Tarsus Pharmaceuticals, Inc. | 16 | $346 |
| Aerie Pharmaceuticals, Inc. | 11 | $269 |
| Harrow Eye, LLC | 8 | $200 |
| Ocular Therapeutix, Inc. | 9 | $196 |
| Mallinckrodt Hospital Products Inc. | 3 | $183 |
| Dompe US, Inc. | 8 | $181 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Kala Pharmaceuticals, Inc. | 5 | $117 |
| Apellis Pharmaceuticals, Inc. | 1 | $83 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $69 |
| Shire North American Group Inc | 4 | $68 |
| Biotissue Holdings Inc. | 3 | $58 |
| NEW World Medical,inc. | 3 | $44 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Eyevance Pharmaceuticals LLC | 2 | $25 |
| Sight Sciences, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPMI Lumera$3,924
- INTRALASE FS FEMTOSEC LASER$2,000
- Tecnis 1-piece IOL$910
- Tecnis Multifocal Family of 1-piece IOLS$910
- Tecnis Symfony IOL$910
- LUMIGAN$247
- CEQUA$236
- TYRVAYA$235
- iDoseTR$187
- iStent inject W$149
- ACTHAR$146
- VYZULTA$142
- EYLEA$125
- Clareon PanOptix Pro$125
- MIEBO$125
- XIIDRA$125
- COMBIGAN$125
- Tecnis Simplicity$125
- XDEMVY$122
- DURYSTA$104
How this compares
$15,039 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $741,964 |
| RestasisCyclosporine | 610 | $739,481 |
| Cyclosporine | 128 | $81,123 |
| RocklatanNetarsudil Mesylat/Latanoprost | 106 | $49,799 |
| MieboPerfluorohexyloctane/Pf | 44 | $49,150 |
| XiidraLifitegrast | 30 | $28,419 |
| LumiganBimatoprost | 64 | $27,294 |
| TyrvayaVarenicline Tartrate | 38 | $24,953 |
| CombiganBrimonidine Tartrate/Timolol | 81 | $22,766 |
| Alphagan PBrimonidine Tartrate | 61 | $21,079 |
| Prednisolone Acetate | 350 | $15,849 |
| VevyeCyclosporine | 14 | $15,522 |
| Latanoprost | 1,204 | $14,418 |
| Brimonidine Tartrate | 91 | $11,299 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 547 | $8,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,850 | $810,620816 claims |
| Dompe US, Inc.Oxervate | $181 | $741,96413 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $642 | $77,56974 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $269 | $58,502134 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $709 | $24,95338 claims |
| Harrow Eye, LLCVevye | $200 | $15,52214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Mandeville
- Blake WilliamsonBaton Rouge$443K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Wyche ColemanShreveport$35K
- Peter KastlNew Orleans$32K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
- Arthur DelahoussayeHouma$26K
- Michael RedmondAlexandria$24K
- Eric ReishAlexandria$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.